Compare
Arvinas, Inc. vs Harrow, Inc. vs Arcus Biosciences, Inc. vs Xeris Biopharma Holdings, Inc.
| Latest fiscal year | Arvinas, Inc. ARVN | Harrow, Inc. HROW | Arcus Biosciences, Inc. RCUS | Xeris Biopharma Holdings, Inc. XERS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $262.60M | $272.30M | $247.00M | $291.85M |
| Revenue growth (YoY) | -0.3% | +36.4% | -4.3% | +43.7% |
| Gross margin | n/a | 75.1% | n/a | n/a |
| Operating margin | -45.1% | 11.2% | -156.3% | 8.5% |
| Net margin | -30.8% | -1.9% | -142.9% | 0.2% |
| Net income | -$80.80M | -$5.14M | -$353.00M | $554.0K |
| EPS (Diluted) | -$1.14 | -$0.14 | -$3.29 | $0.00 |
| Operating cash flow | -$273.80M | $43.86M | -$482.00M | $28.63M |
| Free cash flow | -$275.70M | $42.98M | -$484.00M | n/a |
| Cash & equivalents | $142.90M | $72.93M | $222.00M | $111.04M |
| Total assets | $717.90M | $399.48M | $1.14B | $383.53M |
| Total liabilities | $284.00M | $347.39M | n/a | $369.84M |
| Shareholders' equity | $433.90M | $52.45M | $631.00M | $13.69M |
| Return on year-end equity | -18.6% | -9.8% | -55.9% | 4.0% |
| Shares outstanding | 63.50M | 37.23M | 125.30M | 166.22M |
Revenue, most recent five fiscal years
| Fiscal year | Arvinas, Inc. | Harrow, Inc. | Arcus Biosciences, Inc. | Xeris Biopharma Holdings, Inc. |
|---|---|---|---|---|
| Latest | $262.60M Ended 2025-12-31 | $272.30M Ended 2025-12-31 | $247.00M Ended 2025-12-31 | $291.85M Ended 2025-12-31 |
| 1 year earlier | $263.40M Ended 2024-12-31 | $199.61M Ended 2024-12-31 | $258.00M Ended 2024-12-31 | $203.07M Ended 2024-12-31 |
| 2 years earlier | $78.50M Ended 2023-12-31 | $130.19M Ended 2023-12-31 | $117.00M Ended 2023-12-31 | $163.91M Ended 2023-12-31 |
| 3 years earlier | $131.40M Ended 2022-12-31 | $88.59M Ended 2022-12-31 | $112.00M Ended 2022-12-31 | $110.25M Ended 2022-12-31 |
| 4 years earlier | $53.60M Ended 2021-12-31 | $72.48M Ended 2021-12-31 | $383.00M Ended 2021-12-31 | $49.59M Ended 2021-12-31 |